ClinicalTrials.Veeva

Menu

Study Buddy (an ECA Oncology Trial Advisor) for Cancer Trials

Boston Medical Center (BMC) logo

Boston Medical Center (BMC)

Status

Completed

Conditions

Patient Satisfaction
Patient Compliance
Guideline Adherence

Treatments

Behavioral: Chemo Buddy

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT02742740
5R01CA158219-05 (U.S. NIH Grant/Contract)
H-34989

Details and patient eligibility

About

The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates. The Study Buddy will use the web-based ECA infrastructure developed for use on another project. We will use web browsers on tablets provided to study participants to access the Study Buddy, providing anywhere, anytime access to its functions. Usability metrics will include session time, satisfaction, and error rates.

Full description

Subjects will be identified from among patients on chemotherapy regimens at BMC. With the provider's approval, we will recruit patients for this study.

All subjects will be enrolled for 2 months. After consent, we will collect baseline data. Baseline data is collected after enrollment and before randomization. Baseline data includes:

sociodemographic data PROMIS Mental and Social health the PHQ-9 clinical factors such as medical diagnosis (cancer type and stage) the Short Assessment of Health Literacy-English the Short Portable Mental Status Questionnaire (SPMSQ) for cognitive impairment the Need For Cognition scale contact numbers of two friends or family members who will assist us in establishing contact, if necessary.

The exit interview will be conducted 2 months after the baseline interview, with windows of 2 weeks plus or minus that date. Study staff will attempt to coincide this interview with a clinical visit, to minimize inconvenience for the subject.

Data collected at the exit interview will include:

PROMIS Mental and Social health the PHQ-9 Satisfaction with ECA

Review of the subject's medical chart will be performed bi-weekly while the subject is enrolled. Chart review will be performed by a staff member who is blinded to the subject's group (intervention vs control).

Enrollment

4 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. speaks English fluently
  2. is able to independently consent into this study and parent cancer study
  3. has adequate corrected vision to use the ECA system (based on a 1-minute functional screener)
  4. has adequate hearing to use the ECA system

Exclusion criteria

  1. suicidal or homicidal
  2. currently in police custody
  3. do not live in the Boston area
  4. plan on leaving the Boston area for more than 4 weeks in the next 6 months
  5. score 6 or less on the SPMSQ screening test

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

4 participants in 2 patient groups

Control
No Intervention group
Description:
Standard of care for chemotherapy treatment.
Chemo Buddy
Experimental group
Description:
Subject receives instructions on how to use the personalized touch screen tablet and takes it home for 2 months.
Treatment:
Behavioral: Chemo Buddy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems